Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Decibel Therapeutics, Inc. (DBTX : NSDQ)

• Company Description    Decibel Therapeutics is a clinical-stage biotechnology company. It engages in discovering and developing transformative treatments to restore and improve hearing and balance. Decibel Therapeutics is based in BOSTON. Number of Employees: 62

• Price / Volume Information    Yesterday's Closing Price: $2.32 Daily Weekly Monthly 20 Day Moving Average: 71,295 shares Shares Outstanding: 24.97 (millions) Market Capitalization: $57.92 (millions) Beta: 0.45 52 Week High: $9.75 52 Week Low: $1.84 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.75% 14.61% 12 Week -35.56% -29.15% Year To Date -50.11% -39.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1325 Boylston Street Suite 500 - Boston,MA 02215 USA ph: 617-370-8701 fax: - ir@decibeltx.com None

• General Corporate Information    Officers Laurence Reid - Chief Executive Officer; President and Director William H. Carson - Chairman Elisabeth Leiderman - Chief Financial Officer Neil Exter - Director Alison Finger - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 24343R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 24.97 Most Recent Split Date: (:1) Beta: 0.45 Market Capitalization: $57.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.45 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.62% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -37.06 12/31/21 - -32.11 09/30/21 - -46.15 ROA 03/31/22 - -29.69 12/31/21 - -26.79 09/30/21 - -31.56 Current Ratio 03/31/22 - 8.35 12/31/21 - 7.99 09/30/21 - 9.08 Quick Ratio 03/31/22 - 8.35 12/31/21 - 7.99 09/30/21 - 9.08 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.13 12/31/21 - 5.68 09/30/21 - 6.19 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©